Conjugated estrogens

Generic Name: Conjugated estrogens

Brand Names: Congest, Duavee, Duavive, Premarin, Premphase 28 Day, Prempro 0.625/2.5 28 Day

Drug Type: Small Molecule

CAS Number: 12126-59-9

Unique Ingredient Identifier: IU5QR144QX

Background: The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.

The conjugated estrogen product contains a mix of estrogen from which about 50% is represented by estrone sulfate followed by 25% of equilin sulfate, 15% of 17-alpha-dehydroequilenin sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate. It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine.

The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions. However, until 1986 official clinical trials were performed and this product was determined to be effective for the treatment of osteoporosis. The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.

Indication: The conjugated estrogens are indicated for several different conditions including:

Associated Conditions: Abnormal Uterine Bleeding, Atrophic Vaginitis, Atrophy of vulva, Kraurosis Vulvae, Menopause, Metastatic Breast Cancer, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Androgen-dependent tumor Advanced Prostate Carcinoma, Hypoestrogenism, Moderate Dyspareunia, Moderate Vulvar and Vaginal Atrophy, Severe Dyspareunia, Severe Vulvar and Vaginal Atrophy

Associated Therapies: Estrogen Replacement Therapy, Palliative Treatment

Clinical Trials

Short-Term Hormone Therapy for Menopause Shows No Long-Term Cognitive Harm

6 months ago

• A new study reveals that short-term hormone replacement therapy (HRT) for menopausal symptoms does not negatively impact cognitive function in women over the long term. • The research followed women for 10 years after they completed a 4-year course of HRT and found no significant difference in cognitive performance compared to those who received a placebo. • While HRT does not appear to harm the brain, the study also indicates that it should not be considered a method for improving neurological health during aging. • Researchers emphasize the need for further investigation into the long-term health outcomes of menopausal hormone therapy, including its potential effects on mood and Alzheimer's disease biomarkers.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy